Asian ethnic bridging study
17 evidence topics · 1 source
Objective
Primary and secondary objectives
Location and study date
No evidence found.
Study design
Sequential periods and blood sampling in the Japanese and Chinese cohorts
Caucasian reference cohort given the expected therapeutic dose only
Eligibility criteria
Treatment
Fed-state dosing in the Asian cohorts and fasted-state dosing in the Caucasian cohort on day 7 of twice-daily dosing
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Noncompartmental analysis of the parent drug and its main metabolite
Statistical analysis description
Number of participants (Planned and analyzed)
Single-center open-label enrollment of 24 participants in three cohorts
Description of analysis sets
Descriptive statistics and external Caucasian data in the single-dose plots
Results
Participant disposition
Reason for the single discontinuation due to a treatment-emergent adverse event
Baseline characteristics
Demographics by ethnic cohort
| Characteristic | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) | Overall (n=24) |
|---|---|---|---|---|
| Age (years), mean (SD) | “42.6 (9.3)” | “38.4 (8.2)” | “45.5 (11.8)” | “42.2 (9.9)” |
| Sex, female/male, n (%) | “1 (12.5)/7 (87.5)” | “0 (0.0)/8 (100.0)” | “5 (62.5)/3 (37.5)” | “6 (25.0)/18 (75.0)” |
| Hispanic or Latino, n (%) | “0 (0.0)” | “0 (0.0)” | “2 (25.0)” | “2 (8.3)” |
| Not Hispanic or Latino, n (%) | “8 (100.0)” | “8 (100.0)” | “6 (75.0)” | “22 (91.7)” |
| Height (cm), mean (SD) | “170.2 (8.2)” | “170.0 (3.0)” | “168.6 (7.7)” | “169.6 (6.4)” |
| Weight (kg), mean (SD) | “66.4 (10.2)” | “72.6 (9.7)” | “80.4 (8.1)” | “73.1 (10.7)” |
Efficacy results
Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort
| Parameter | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) |
|---|---|---|---|
| Cmax,ss (ng/mL), geometric mean (CV%) | “502 (25.1)” | “586 (24.3)” | “531 (11.1)” |
| AUC0-τ,ss (hr*ng/mL), geometric mean (CV%) | “3,410 (22.7)” | “4,580 (18.3)” | “3,530 (9.5)” |
| Tmax,ss (hr), median (min, max) | “2.8 (2.0, 4.0)” | “3.0 (1.0, 6.0)” | “1.0 (1.0, 2.0)” |
| t1/2,ss (hr), geometric mean (CV%) | “7.6 (20.4)” | “8.4 (13.4)” | “9.1 (17.0)” |
| CL/F (L/hr), geometric mean (CV%) | “10.8 (22.7)” | “8.0 (18.3)” | “10.4 (9.5)” |
| Vd/F (L), geometric mean (CV%) | “118.0 (35.9)” | “97.4 (26.5)” | “138.0 (17.7)” |
| BWCmax (ng/mL/mg/kg), geometric mean (CV%) | “895 (32.5)” | “1,140 (14.3)” | “1,140 (12.6)” |
| BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%) | “6,080 (26.9)” | “8,950 (9.8)” | “7,540 (11.4)” |
| Rac, geometric mean (CV%) | “2.10 (96.3)” | “2.48 (38.0)” | “2.09 (34.7)” |
| MRCmax main metabolite, geometric mean (CV%) | “2.65 (33.6)” | “2.91 (23.1)” | “2.60 (24.9)” |
| MRAUC main metabolite, geometric mean (CV%) | “3.56 (30.3)” | “3.69 (24.9)” | “3.73 (15.8)” |
Comparability of absorption, exposure, elimination, and food effect across ethnicities
Conclusion on dosing in Asian populations
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by dose period and ethnic cohort
| Event | 20 mg, Japanese (n=8) | 20 mg, Chinese (n=8) | 40 mg, Japanese (n=8) | 40 mg, Chinese (n=8) | 40 mg BID, Japanese (n=8) | 40 mg BID, Chinese (n=8) | 40 mg BID, Caucasian (n=8) |
|---|---|---|---|---|---|---|---|
| Any TEAE, n (%) | “1 (12.5)” | “2 (25.0)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “5 (62.5)” | “6 (75.0)” |
| At least 1 TEAE Grade 2, n (%) | “0 (0.0)” | “1 (12.5)” | “0 (0.0)” | “1 (12.5)” | “1 (12.5)” | “0 (0.0)” | “4 (50.0)” |
| At least 1 TEAE Grade ≥3, n (%) | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| TEAE related to study medication | “1 (12.5)” | “1 (12.5)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “4 (50.0)” | “6 (75.0)” |
| TEAEs leading to study discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
| TEAEs leading to study medication discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
Tolerability, severity, and most common events by ethnic cohort
Study limitations
Summary
- The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
- The study was single-center and open-label, with 24 healthy participants (8 per cohort).
- The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
- Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
- The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.